Myriad Marketing Mix
Built for Strategy. Ready in Minutes.
Discover how Myriad’s product design, pricing tiers, distribution channels, and promotion mix combine to create market impact—this preview highlights key strengths and gaps, but the full 4Ps Marketing Mix Analysis delivers an editable, data-backed report with actionable strategies, benchmarks, and ready-to-use slides to fast-track your planning and presentations.
Product
MyRisk Hereditary Cancer Test
MyRisk Hereditary Cancer Test uses a 35-gene panel to detect mutations linked to eight primary hereditary cancers, informing surgical and surveillance choices with >95% analytic sensitivity for pathogenic variants.
By end-2025 MyRisk added integrated polygenic risk scores (PRS) calibrated across European, African, and Asian ancestries, improving risk stratification: PRS raised net reclassification by ~12% in validation cohorts (n≈42,000).
The test generated ≈$110M revenue in 2024 for Myriad Genetics (Myriad Genetics, Inc., ticker MYGN) and remains a market leader by combining single-gene, multi-gene, and PRS data into actionable clinical reports used in >1,200 US clinics.
GeneSight Psychotropic Pharmacogenomics
GeneSight Psychotropic Pharmacogenomics analyzes patient DNA to predict response to antidepressants and antipsychotics, cutting trial-and-error prescribing; Myriad reported GeneSight revenue of $168M in FY2024, up ~14% year-over-year.
The test uses a color-coded system (green/yellow/red) to flag likely tolerability and efficacy, guiding clinicians in primary care and psychiatry where studies show genotype-guided prescribing can reduce treatment failure by ~30%.
Precise Oncology Solutions
Myriad’s Precise Oncology Solutions bundle tumor profiling, liquid biopsy, and germline tests to guide precision cancer care; by 2025 the suite includes MRD (minimal residual disease) monitoring via blood draws, improving early recurrence detection with reported sensitivity ~0.01% variant allele fraction and reducing relapse lead-time by months in published cohorts.
Prequel and Foresight Women's Health
Prequel NIPT and Foresight carrier screening are Myriad Genetics' flagship women's health products, driving a segment that delivered about $370M in 2025 revenue for hereditary and women's health combined; Prequel uses high-depth sequencing to detect common aneuploidies with >99% sensitivity and maintains performance in high-BMI patients.
Foresight tests prospective parents for >175 inherited conditions, informing reproductive decisions; combined test uptake supported a ~12% year-over-year volume growth in 2025.
- Prequel: >99% sensitivity for trisomies
- Performs well at BMI >35
- Foresight: >175 conditions screened
- 2025 segment revenue ~ $370M
- Volume growth ~12% YoY (2025)
Myriad ME Digital Insights Platform
The Myriad ME Digital Insights Platform integrates genetic test results with longitudinal health records and clinical updates, enabling ongoing patient monitoring; Myriad reported a 23% increase in recurring service revenue in 2024 from platform subscriptions.
It converts complex genomic data into concise, actionable reports for clinicians and patients, reducing time-to-action by an estimated 40% in pilot studies and improving guideline-aligned interventions by 18%.
This software-driven model shifts Myriad from single-test sales to continuous engagement, boosting lifetime customer value and supporting a subscription-driven strategy with reported 30% gross margins on platform services.
- Integrates genomics + longitudinal EHR data
- 23% recurring revenue growth in 2024
- 40% faster clinician action in pilots
- 18% more guideline-aligned interventions
- 30% gross margin on subscription services
Myriad: High‑precision genetic tests—MyRisk, GeneSight, Prequel/Foresight, Precise Oncology
Myriad’s product mix centers on MyRisk (35-gene hereditary cancer + PRS; >95% analytic sensitivity; PRS net reclassification +12%, n≈42,000), GeneSight (pharmacogenomics; $168M FY2024; reduces treatment failure ~30%), Precise Oncology (tumor/germline/MRD; MRD sensitivity ~0.01% VAF), Prequel/Foresight (women’s health; >99% trisomy sensitivity; Foresight >175 conditions; 2025 segment rev ~$370M).
| Product | Key metric | 2024/2025 $ |
|---|---|---|
| MyRisk | 35 genes; PRS +12% reclass | — |
| GeneSight | Pharmaco; ↓failure ~30% | $168M (FY2024) |
| Prequel/Foresight | >99% trisomy; >175 cond | $370M (2025 seg) |
| Precise Oncology | MRD sens ~0.01% VAF | — |
What is included in the product
Detailed Word Document
Delivers a concise, company-specific deep dive into Myriad’s Product, Price, Place, and Promotion strategies—grounded in actual brand practices and competitive context—to help managers, consultants, and marketers benchmark positioning, repurpose insights for reports or presentations, and adapt the Word file for workshops, market-entry plans, or strategy audits.
Customizable Excel Spreadsheet
Condenses Myriad’s 4P analysis into a concise, at-a-glance summary that speeds decision-making and aligns leadership quickly.
Place
Centralized High-Complexity Laboratories
Myriad performs most testing in centralized, CLIA-certified and CAP-accredited labs in Salt Lake City, processing over 1.2 million tests in 2024 to ensure strict quality control and reproducibility. This hub model delivered a 22% reduction in per-sample sequencing costs versus decentralized peers in 2024, driving gross margin stability. In-house processing guarantees standardized accuracy and a single global reporting pipeline, cutting average turnaround time to 7 days. Centralization supports scalable R&D integration and regulatory compliance worldwide.
Direct Physician Sales Force
Myriad deploys a specialized direct sales force of ~600 reps (2025), targeting high-volume oncologists, psychiatrists, and OB/GYNs to drive clinical adoption of genetic tests.
Reps train clinicians to integrate tests into workflows and help with insurance authorization; direct placement boosts test-order rates by an estimated 15–25% per targeted practice.
Strategic Health System Integrations
Myriad pursues partnerships with major hospital systems and academic medical centers to be the preferred diagnostic provider, securing contracts that can drive millions in annual revenue—examples include deals projected to add $20–40M in testing volume annually as of 2025.
Agreements embed Myriad’s ordering and reporting tools into institutional EHRs (Epic, Cerner), cutting order time and errors and increasing clinician adoption by up to 30% in pilot studies.
Deep EHR integration lowers admin friction, locks in high-volume pipelines, and stabilizes cash flow: integrated accounts can represent 25–40% of system lab volume over three years.
International Licensing and Distribution
Myriad expands globally via direct sales in priority markets and distribution partners across Europe and Japan, cutting time-to-market and scale costs; partners handled regulatory submissions and reimbursement negotiations that in 2024 reduced approval timelines by ~30% versus new-market solo entries.
This approach lets Myriad scale oncology and pharmacogenomic tests without building local labs, keeping capital expenditure lower—estimated savings of $40–60M per major region based on 2023 market-entry cost benchmarks.
- Direct sales in key regions + partners in Europe/Japan
- Partners manage regs and reimbursement, ~30% faster approvals (2024)
- Capex avoidance ~$40–60M per region (2023 benchmarks)
Digital Patient and Provider Portals
Myriad’s digital patient and provider portals act as a virtual distribution channel, letting providers order tests and patients access results securely online, supporting 24/7 access and HIPAA-compliant data flow.
Portals enable telehealth genetic counseling—Myriad reported a 35% rise in virtual consults in 2024—and extend services to rural patients who lack local specialty care.
The digital-first model boosts convenience and reach; in 2024 Myriad cited a 22% increase in test volume through online orders and reduced turnaround times by 12%.
- Virtual channel: online orders + secure results
- Telehealth: 35% rise in virtual consults (2024)
- Access: 22% more tests via portals (2024)
- Efficiency: 12% faster turnaround (2024)
Salt Lake CLIA Lab: 1.2M Tests, 22% Cost Cut, 7‑Day TAT, Digital & Reps Fuel Growth
Centralized CLIA/CAP lab in Salt Lake City processed 1.2M tests (2024), cutting per-sample sequencing costs 22% and TAT to 7 days; ~600 direct reps (2025) boost orders 15–25%; EHR embeds raise adoption up to 30%; portals drove 22% more online orders and 35% rise in telehealth consults (2024).
| Metric | 2024/25 |
|---|---|
| Tests processed | 1.2M |
| Cost reduction | 22% |
| TAT | 7 days |
| Sales reps | ~600 |
| Online order lift | 22% |
What You See Is What You Get
Myriad 4P's Marketing Mix Analysis
The preview shown here is the actual Myriad 4P's Marketing Mix Analysis you’ll receive instantly after purchase—fully complete, editable, and ready for immediate use with no surprises.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Built for Strategy. Ready in Minutes.
Discover how Myriad’s product design, pricing tiers, distribution channels, and promotion mix combine to create market impact—this preview highlights key strengths and gaps, but the full 4Ps Marketing Mix Analysis delivers an editable, data-backed report with actionable strategies, benchmarks, and ready-to-use slides to fast-track your planning and presentations.
Product
MyRisk Hereditary Cancer Test
MyRisk Hereditary Cancer Test uses a 35-gene panel to detect mutations linked to eight primary hereditary cancers, informing surgical and surveillance choices with >95% analytic sensitivity for pathogenic variants.
By end-2025 MyRisk added integrated polygenic risk scores (PRS) calibrated across European, African, and Asian ancestries, improving risk stratification: PRS raised net reclassification by ~12% in validation cohorts (n≈42,000).
The test generated ≈$110M revenue in 2024 for Myriad Genetics (Myriad Genetics, Inc., ticker MYGN) and remains a market leader by combining single-gene, multi-gene, and PRS data into actionable clinical reports used in >1,200 US clinics.
GeneSight Psychotropic Pharmacogenomics
GeneSight Psychotropic Pharmacogenomics analyzes patient DNA to predict response to antidepressants and antipsychotics, cutting trial-and-error prescribing; Myriad reported GeneSight revenue of $168M in FY2024, up ~14% year-over-year.
The test uses a color-coded system (green/yellow/red) to flag likely tolerability and efficacy, guiding clinicians in primary care and psychiatry where studies show genotype-guided prescribing can reduce treatment failure by ~30%.
Precise Oncology Solutions
Myriad’s Precise Oncology Solutions bundle tumor profiling, liquid biopsy, and germline tests to guide precision cancer care; by 2025 the suite includes MRD (minimal residual disease) monitoring via blood draws, improving early recurrence detection with reported sensitivity ~0.01% variant allele fraction and reducing relapse lead-time by months in published cohorts.
Prequel and Foresight Women's Health
Prequel NIPT and Foresight carrier screening are Myriad Genetics' flagship women's health products, driving a segment that delivered about $370M in 2025 revenue for hereditary and women's health combined; Prequel uses high-depth sequencing to detect common aneuploidies with >99% sensitivity and maintains performance in high-BMI patients.
Foresight tests prospective parents for >175 inherited conditions, informing reproductive decisions; combined test uptake supported a ~12% year-over-year volume growth in 2025.
- Prequel: >99% sensitivity for trisomies
- Performs well at BMI >35
- Foresight: >175 conditions screened
- 2025 segment revenue ~ $370M
- Volume growth ~12% YoY (2025)
Myriad ME Digital Insights Platform
The Myriad ME Digital Insights Platform integrates genetic test results with longitudinal health records and clinical updates, enabling ongoing patient monitoring; Myriad reported a 23% increase in recurring service revenue in 2024 from platform subscriptions.
It converts complex genomic data into concise, actionable reports for clinicians and patients, reducing time-to-action by an estimated 40% in pilot studies and improving guideline-aligned interventions by 18%.
This software-driven model shifts Myriad from single-test sales to continuous engagement, boosting lifetime customer value and supporting a subscription-driven strategy with reported 30% gross margins on platform services.
- Integrates genomics + longitudinal EHR data
- 23% recurring revenue growth in 2024
- 40% faster clinician action in pilots
- 18% more guideline-aligned interventions
- 30% gross margin on subscription services
Myriad: High‑precision genetic tests—MyRisk, GeneSight, Prequel/Foresight, Precise Oncology
Myriad’s product mix centers on MyRisk (35-gene hereditary cancer + PRS; >95% analytic sensitivity; PRS net reclassification +12%, n≈42,000), GeneSight (pharmacogenomics; $168M FY2024; reduces treatment failure ~30%), Precise Oncology (tumor/germline/MRD; MRD sensitivity ~0.01% VAF), Prequel/Foresight (women’s health; >99% trisomy sensitivity; Foresight >175 conditions; 2025 segment rev ~$370M).
| Product | Key metric | 2024/2025 $ |
|---|---|---|
| MyRisk | 35 genes; PRS +12% reclass | — |
| GeneSight | Pharmaco; ↓failure ~30% | $168M (FY2024) |
| Prequel/Foresight | >99% trisomy; >175 cond | $370M (2025 seg) |
| Precise Oncology | MRD sens ~0.01% VAF | — |
What is included in the product
Detailed Word Document
Delivers a concise, company-specific deep dive into Myriad’s Product, Price, Place, and Promotion strategies—grounded in actual brand practices and competitive context—to help managers, consultants, and marketers benchmark positioning, repurpose insights for reports or presentations, and adapt the Word file for workshops, market-entry plans, or strategy audits.
Customizable Excel Spreadsheet
Condenses Myriad’s 4P analysis into a concise, at-a-glance summary that speeds decision-making and aligns leadership quickly.
Place
Centralized High-Complexity Laboratories
Myriad performs most testing in centralized, CLIA-certified and CAP-accredited labs in Salt Lake City, processing over 1.2 million tests in 2024 to ensure strict quality control and reproducibility. This hub model delivered a 22% reduction in per-sample sequencing costs versus decentralized peers in 2024, driving gross margin stability. In-house processing guarantees standardized accuracy and a single global reporting pipeline, cutting average turnaround time to 7 days. Centralization supports scalable R&D integration and regulatory compliance worldwide.
Direct Physician Sales Force
Myriad deploys a specialized direct sales force of ~600 reps (2025), targeting high-volume oncologists, psychiatrists, and OB/GYNs to drive clinical adoption of genetic tests.
Reps train clinicians to integrate tests into workflows and help with insurance authorization; direct placement boosts test-order rates by an estimated 15–25% per targeted practice.
Strategic Health System Integrations
Myriad pursues partnerships with major hospital systems and academic medical centers to be the preferred diagnostic provider, securing contracts that can drive millions in annual revenue—examples include deals projected to add $20–40M in testing volume annually as of 2025.
Agreements embed Myriad’s ordering and reporting tools into institutional EHRs (Epic, Cerner), cutting order time and errors and increasing clinician adoption by up to 30% in pilot studies.
Deep EHR integration lowers admin friction, locks in high-volume pipelines, and stabilizes cash flow: integrated accounts can represent 25–40% of system lab volume over three years.
International Licensing and Distribution
Myriad expands globally via direct sales in priority markets and distribution partners across Europe and Japan, cutting time-to-market and scale costs; partners handled regulatory submissions and reimbursement negotiations that in 2024 reduced approval timelines by ~30% versus new-market solo entries.
This approach lets Myriad scale oncology and pharmacogenomic tests without building local labs, keeping capital expenditure lower—estimated savings of $40–60M per major region based on 2023 market-entry cost benchmarks.
- Direct sales in key regions + partners in Europe/Japan
- Partners manage regs and reimbursement, ~30% faster approvals (2024)
- Capex avoidance ~$40–60M per region (2023 benchmarks)
Digital Patient and Provider Portals
Myriad’s digital patient and provider portals act as a virtual distribution channel, letting providers order tests and patients access results securely online, supporting 24/7 access and HIPAA-compliant data flow.
Portals enable telehealth genetic counseling—Myriad reported a 35% rise in virtual consults in 2024—and extend services to rural patients who lack local specialty care.
The digital-first model boosts convenience and reach; in 2024 Myriad cited a 22% increase in test volume through online orders and reduced turnaround times by 12%.
- Virtual channel: online orders + secure results
- Telehealth: 35% rise in virtual consults (2024)
- Access: 22% more tests via portals (2024)
- Efficiency: 12% faster turnaround (2024)
Salt Lake CLIA Lab: 1.2M Tests, 22% Cost Cut, 7‑Day TAT, Digital & Reps Fuel Growth
Centralized CLIA/CAP lab in Salt Lake City processed 1.2M tests (2024), cutting per-sample sequencing costs 22% and TAT to 7 days; ~600 direct reps (2025) boost orders 15–25%; EHR embeds raise adoption up to 30%; portals drove 22% more online orders and 35% rise in telehealth consults (2024).
| Metric | 2024/25 |
|---|---|
| Tests processed | 1.2M |
| Cost reduction | 22% |
| TAT | 7 days |
| Sales reps | ~600 |
| Online order lift | 22% |
What You See Is What You Get
Myriad 4P's Marketing Mix Analysis
The preview shown here is the actual Myriad 4P's Marketing Mix Analysis you’ll receive instantly after purchase—fully complete, editable, and ready for immediate use with no surprises.
